Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice
- Authors
- Park, Kyung-Yeon; Oh, Euichaul; Kwak, Mi-Kyoung; Jun, Hyun Sik; Heo, Tae-Hwe
- Issue Date
- 7-3월-2016
- Publisher
- PUBLIC LIBRARY SCIENCE
- Citation
- PLOS ONE, v.11, no.3
- Indexed
- SCIE
SCOPUS
- Journal Title
- PLOS ONE
- Volume
- 11
- Number
- 3
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/89231
- DOI
- 10.1371/journal.pone.0150791
- ISSN
- 1932-6203
- Abstract
- Pravastatin is a lipid-lowering agent that attenuates atherosclerosis. However, the multifactorial pathogenesis of atherosclerosis requires other drugs with different anti-atherogenic mechanisms. We chose sarpogrelate as an anti-platelet agent and a novel component of a complex drug with pravastatin due to its high potential but little information on its beneficial effects on atherosclerosis. Low-density lipoprotein receptor-knockout mice were fed a highfat, high-cholesterol diet and treated with pravastatin alone, sarpogrelate alone, or a combination of both drugs. Although sarpogrelate alone did not significantly reduce atherosclerotic plaque areas, co-treatment with pravastatin significantly decreased aortic lesions compared to those of the pravastatin alone treated group. The combined therapy was markedly more effective than that of the single therapies in terms of foam cell formation, smooth muscle cell proliferation, and inflammatory cytokine levels. These results suggest that pravastatin and sarpogrelate combined therapy may provide a new therapeutic strategy for treating atherosclerosis.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biotechnology and Bioinformatics > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.